{"disease":{"id":"dystrophic-epidermolysis-bullosa","name":"dystrophic epidermolysis bullosa"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06423573","title":"A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez","phase":"","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"Amryt Pharma","has_results":false},{"nct_id":"NCT05033574","title":"The State of Sexual Development in Children With Inherited Epidermolysis Bullosa","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"National Medical Research Center for Children's Health, Russian Federation","has_results":false},{"nct_id":"NCT04917887","title":"Long-Term Follow-up Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":false},{"nct_id":"NCT04917874","title":"A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":false},{"nct_id":"NCT06594393","title":"A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Xinnate AB","has_results":false},{"nct_id":"NCT04491604","title":"Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":true},{"nct_id":"NCT02178969","title":"Short Term Observational Study in DEB Patients","phase":"","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT04757727","title":"Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)","phase":"","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT07230223","title":"Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Isfahan University of Medical Sciences","has_results":false},{"nct_id":"NCT03529877","title":"Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"RHEACELL GmbH & Co. KG","has_results":false},{"nct_id":"NCT03536143","title":"A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Krystal Biotech, Inc.","has_results":true},{"nct_id":"NCT05725018","title":"A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Abeona Therapeutics, Inc","has_results":false},{"nct_id":"NCT01263379","title":"Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Abeona Therapeutics, Inc","has_results":true},{"nct_id":"NCT03752905","title":"A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Phoenix Tissue Repair, Inc.","has_results":false},{"nct_id":"NCT04227106","title":"Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Abeona Therapeutics, Inc","has_results":false},{"nct_id":"NCT03472287","title":"To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Castle Creek Pharmaceuticals, LLC","has_results":true},{"nct_id":"NCT03392909","title":"Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT05529134","title":"Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":8,"lead_sponsor_name":"Phoenicis Therapeutics","has_results":false},{"nct_id":"NCT04599881","title":"A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Phoenix Tissue Repair, Inc.","has_results":false},{"nct_id":"NCT03012191","title":"Gentamicin for RDEB","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT05157958","title":"Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Anterogen Co., Ltd.","has_results":false},{"nct_id":"NCT05944250","title":"A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT02698735","title":"Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT04520022","title":"Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT03578029","title":"Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Lenus Therapeutics, LLC","has_results":false},{"nct_id":"NCT02984085","title":"Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Holostem s.r.l.","has_results":false},{"nct_id":"NCT04177498","title":"Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT03183934","title":"A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial","phase":"","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Anterogen Co., Ltd.","has_results":false},{"nct_id":"NCT05143190","title":"Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Phoenix Tissue Repair, Inc.","has_results":false},{"nct_id":"NCT03605069","title":"A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Phoenicis Therapeutics","has_results":false},{"nct_id":"NCT02579369","title":"Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Anterogen Co., Ltd.","has_results":false}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}